Matsukiyococokara & Co. · TSE:3088
Matsukiyococokara & — FY2024 Earnings Presentation
17 slides from Matsukiyococokara &'s earnings presentation, May 9, 2025
Slide 1: Supplementary Presentation: Financial Results for the Fiscal Year Ended March 31, 2025
This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail. Supplementary Presentation Financial Results for the Fiscal Year Ended March 31, 2025 Copyright 2
Slide 2: Table of contents
Table of contents Financial Results for FY2024 Financial Summary YoY (Full Year) ・・・・・・ 3 Segment Results YoY (Full Year) ・・・・・・ 4 Segment Results YoY (Full Year) (Reference) ・・・・・・ 5 Excluding amortization of goodwill and trademark rights associated with the management integration with cocokarafine
Slide 3: Financial Summary YoY (Full Year)
Financial Results for FY2024 Financial Summary YoY(Full Year) ◼ Sales increased due to strong performance mainly in cosmetics due to people's flow expansion, an increase in duty- free sales, and the strengthening of the development of seasonal products. ◼ Profit increased due to the control of expen
Slide 4: Segment Results YoY (Full Year)
Financial Results for FY2024 Segment Results YoY(Full Year) ◼ The expansion of people's flow in urban and downtown areas and the increase in the number of foreign tourists visiting Japan are among the factors that have impacted the Matsumotokiyoshi Group's businesses.Increase in both sales and profi
Slide 5: Segment Results YoY (Full Year) (Reference)
Financial Results for FY2024 Segment Results YoY(Full Year) Excluding amortization of goodwill and trademark rights totaling 7,237 million yen Reference associated with the management integration with cocokarafine Inc. (Millions of yen) FY2023 FY2024 Change Change (amount) (%) Profitable Profitable
Slide 6: Net Sales by Product
Financial Results for FY2024 Net Sales by Product ◼ Health and Beauty category grew due to the strengthening of the development of seasonal products and efficient and effective sales promotion measures, etc. ◼ Gross profit margin improved due to increased sales of high value-added products such as p
Slide 7: Balance Sheet
Financial Results for FY2024 Balance Sheet ◼ Equity ratio 73.1％ (Millions of yen) End of March, 2024 End of March, 2025 Change Current assets 370,798 364,316 (6,481) Cash and deposits 117,720 111,750 (5,970) Accounts receivable - trade 61,747 64,469 2,721 Merchandise 138,573 144,168 5,594 Non-curren
Slide 8: Statement of Cash Flows
Financial Results for FY2024 Statement of Cash Flows ◼ Net cash provided by operating activities was approximately 81.4 billion yen mainly due to the recognition of profit before income taxes. ◼ We have continued to actively and systematically implement shareholder returns, with share buybacks of ap
Slide 9: Store Openings, Closings, and Renovations in Japan
Financial Results for FY2024 Store Openings, Closings, and Renovations in Japan ◼ Given the rising costs of land and building rent, construction costs, and consumables, we will focus on opening stores carefully so that they can contribute to our business performance. ◼ Promoted scrap-and-build to re
Slide 10: FY2025 Financial Forecasts
Financial Forecasts for FY2025 FY2025 Financial Forecasts (Millions of yen) First Half 1H FY2024 1H FY2025 Change Change % to net sales % to net sales (amount) (%) Net sales 525,729 544,500 18,770 3.6 Gross profit 182,357 34.7 193,000 35.5 10,642 5.8 SG & A 144,694 27.5 153,500 28.2 8,805 6.1 Operat
Slide 11: Store openings, closings, and renovations plan in Japan
Financial Forecasts for FY2025 Store openings, closings, and renovations plan in Japan ◼ Focus on careful store openings in light of rising rents, construction costs, and supplies costs. ◼ Promoted scrap-and-build to respond to changes in store history, sales floor space, and market area. (Unit: No.
Slide 12: Shareholder Return Policy
Financial Forecasts for FY2025 Shareholder Return ◼ We have set a target dividend on equity (DOE) ratio of 6% and a dividend payout ratio of 50% for the fiscal year ending March 31, 2031. ◼ Maintain or increase dividends Progressive dividend policy. ◼ We will flexibly implement share buyback, taking
Slide 13: (Information) Medium-term Management Plan
(Information) Medium-term Management Plan (Fiscal Year Ended March 31, 2026 to Fiscal Year Ended March 31, 2031) ◼ We have newly formulated a medium-term management plan for the fiscal year ending March 31, 2026 to the fiscal year ending March 31, 2031. 35円 ◼ Medium-term Management Plan 【Japanese】ht
Slide 14: Quarterly Consolidated Financial Results
【Appendix】 Quarterly Consolidated Financial Results FY2023 FY2024 （Millions of yen/%） 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Net sales 248,222 259,544 262,566 252,197 1,022,531 259,749 265,979 275,791 260,105 1,061,626 Gross profit 84,199 89,627 91,074 89,197 354,097 89,241 93,115 96,201 93,676
Slide 15: Quarterly Segment Results
【Appendix】 Quarterly Segment Results FY2023 FY2024 （Millions of yen/％） 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Sales 152,810 159,867 162,999 157,439 633,117 162,010 166,075 173,795 165,346 667,226 Matsumoto- kiyoshi Segment profit 11,783 12,937 14,267 12,753 51,741 12,560 13,647 16,242 15,501 57
Slide 16: Quarterly Net Sales and Gross Profit by Product
【Appendix】 Quarterly Net Sales and Gross Profit by Product FY2023 FY2024 (Millions of yen/％) 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Sales 85,192 91,340 93,264 92,095 361,892 88,378 90,809 96,478 93,085 368,752 Medical and pharmaceuti Segment profit 35,218 40,039 40,416 40,961 156,636 37,069 40,
Slide 17: Cautionary Statement
Cautionary Statement This document contains future outlooks such as plans, forecasts, strategies, and others which are not historical fact and these are made by the management’s judgement based on the obtainable information at the time of the disclosure. Actual results may significantly differ from